Mounjaro 7.5mg Kwikpen
By ELI LILLY AND COMPANY
Refrigerated
2.4ml Solution For Injection in Pre Filled Pen
₹18562.50
✱
₹20625.00
10% OFF
₹7734.37/ml
(Inclusive of all taxes)
✱
Offer applicable on order above ₹10003 days return policyRead More
All the Products are packed and stored Safely
Description
Mounjaro 7.5mg Kwikpen takes a unique approach to managing type 2 diabetes and weight-related issues (obesity). Unlike traditional medications that target a single hormone pathway, Mounjaro simultaneously stimulates two key hormone receptors: GIP and GLP-1. These are natural hormone systems in the body that play a crucial role in regulating blood sugar levels and reducing appetite.
Due to its dual-action mechanism, Mounjaro has been shown to be particularly effective for adults with type 2 diabetes when combined with dietary modifications and regular exercise, enhancing blood glucose control. It’s also prescribed for weight management in individuals who are overweight (with increased risk of heart diseases, obstructive sleep apnea, high blood pressure, joint problems) or those living with obesity.
Mounjaro 7.5mg Kwikpen works in sync with your body by imitating the effects of natural hormones. It helps your pancreas release insulin only when needed and encourages a sense of fullness even after smaller meals, supporting both blood sugar regulation and healthy weight loss.
Mounjaro can also be beneficial for managing blood sugar in individuals with certain types of kidney and liver disease, when prescribed under the guidance of an expert.
Mounjaro must be used with caution in individuals who fall under special population categories, such as pregnant or lactating women, pediatric patients, and the elderly. Below is a detailed overview for each group to help healthcare professionals and patients make informed decisions.
Mounjaro 7.5mg Kwikpen is not recommended for those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Pregnant individuals or those planning to conceive should avoid this medication due to potential risks to the developing baby.
Before starting this treatment, please inform your doctor of all other medications you are taking to prevent interactions.
Product Summary
| Offer Price | ₹18562.50 |
| You Save | ₹2062.50 (10% on MRP) |
| Contains | Tirzepatide(7.5 Mg/0.6ml) |
| Uses | Type 2 diabetes mellitus and management of obesity |
| Side effects | Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. |
| Therapy | ANTI-DIABETIC |
Uses
- Mounjaro is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Clinical Usage:
- Second-line therapy when metformin is contraindicated or insufficient
- Combination therapy with other antidiabetic medications
- Alternative to insulin therapy in appropriate patients
- Management of patients requiring both glycemic control and weight reduction
- Mounjaro should be taken as and when prescribed by a doctor for:
- Adults (≥18 years) with confirmed type 2 diabetes when metformin, dietary modifications, and exercise fail to achieve desired blood sugar control.
- Inadequate blood sugar management despite lifestyle modifications
- HbA1c ≥7% or as clinically appropriate
- Patients requiring weight management alongside diabetes management, depending on the BMI and associated comorbidities
Contraindications
- Administering Maounjaro is contraindicated in the following situations or conditions:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Hypersensitivity to Tirzepatide or any of its components
- Previous serious allergic reactions to GLP-1 receptor agonists
Side effects
- Abdominal pain
- Constipation
- Indigestion
- Nausea
- Diarrhea
- Vomiting
- Other Common Effects:
- Decreased appetite
- Hypoglycemia (drop in blood sugar below 70 mg/dL)
- Injection site reactions
Precautions and Warnings
Pregnancy
Q:
Can I take Mounjaro solution for injection during pregnancy?
A:
Mounjaro solution for injection is not advised during pregnancy and in women of childbearing potential who are not using contraception. If a patient plans to become pregnant, tirzepatide should be discontinued at least one month prior to the intended pregnancy due to its long half-life. Mounjaro solution for injection must not be used during pregnancy.
Breast Feeding
Q:
Can I take Mounjaro solution for injection while breastfeeding?
A:
Consult your doctor before using Mounjaro solution for injection while breastfeeding, as there is limited safety information regarding the use of this injection during that breastfeeding.
Driving
Q:
Can I drive if I have taken Mounjaro solution for injection?
A:
Mounjaro solution for injection has no or negligible influence on the ability to drive or operate machinery. When tirzepatide is used with a sulphonylurea or insulin, take precautions against hypoglycaemia when driving or operating machinery.
Alcohol
Q:
Can I consume alcohol with Mounjaro solution for injection?
A:
No known interactions with alcohol.
Other General Warnings
Talk to your doctor if
- You have a history of pancreatitis.
- You experience severe abdominal pain, nausea, or vomiting, which could indicate pancreatitis.
- You have type 2 diabetes and are taking insulin or a sulfonylurea, as you may be at an increased risk of hypoglycemia.
- You experience frequent nausea, vomiting, or diarrhoea, which may lead to dehydration and kidney issues.
- You have kidney disease, have had a kidney transplant, or have liver disease.
- You are elderly, especially if you are over 85 years old, as there is limited data on safety in this age group.
- You have a disease of the gallbladder or experience symptoms such as abdominal pain, yellowing of the skin or eyes (jaundice), clay-coloured stools, and fever.
- You have severe gastrointestinal disease, including gastroparesis (delayed emptying of the stomach due to reduced movement), as this injection has not been studied in such patients.
- You have eye problems, such as diabetic retinopathy or diabetic macular oedema, as this injection should be used cautiously in these conditions.
- You are scheduled for a procedure requiring general anaesthesia or deep sedation, as there is an increased risk of pulmonary aspiration.
- You notice any unusual changes in your vision while using this injection.
Directions for Use
- Before using your Mounjaro 7.5mg Kwikpen, allow it to reach room temperature. Always check the vial label to confirm you have the correct medicine and dose, and ensure it has not expired. Examine the pen carefully to make sure it's not damaged. The medicine inside should be clear to slightly yellow in colour, not frozen or cloudy, and free of any particles....
- If anything appears unusual, do not use the vial and contact your healthcare provider immediately.
- Wash your hands thoroughly with soap and water. Choose your injection site on your thigh, upper arm, or stomach area.
- Rotate injection sites to prevent lipodystrophy.
- You may administer an injection of Mounjaro and insulin in the same body area (e.g., the abdomen), but not directly adjacent to each other.
- Administer on the same day each week.
- Can be taken with or without food.
- Store in a refrigerator (2°C to 8°C) until use.
- Do not reuse pens or share them with others.
Storage and disposal
- Store Mounjaro 7.5mg Kwikpen in a refrigerator at 2°C to 8°C.
- If necessary, each single-dose pen or vial can be stored unrefrigerated at temperatures not exceeding 30 °C for up to 21 days.
- Do not freeze. Do not use if frozen.
- Store it in the original carton to protect it from light.
Quick Tips
- To help keep your blood sugar levels steady, take Mounjaro 7.5mg Kwikpen on the same day each week. Setting a reminder can help you stay on track.
- Rotate your injection sites (such as the abdomen, thigh, or upper arm) weekly to prevent skin irritation, bruising, or lumps.
- Regularly check your blood sugar to monitor for signs of low blood sugar, especially if you are on other diabetes medications.
- Eat small, frequent, and balanced meals, and avoid greasy or heavy foods to minimise nausea. Make sure to stay hydrated by drinking plenty of water, especially if you experience nausea, vomiting, or diarrhoea....
- Be aware of serious side effects such as intense stomach pain, signs of pancreatitis (like pain radiating to the back with nausea or fever), or allergic reactions. Contact your doctor immediately if any of these occur....
- Mounjaro 7.5mg Kwikpen may interfere with oral contraceptives. To prevent unintended pregnancy, use a backup birth control method (such as condoms), an intrauterine device (IUD) or switch to a non-oral contraceptive for four weeks after starting treatment and for four weeks after any dose increase....
- Inform your doctor or surgeon that you’re using Mounjaro 7.5mg Kwikpen if you have surgery scheduled, as it may slow down how your stomach empties and increase the risk of complications during anaesthesia....
- Mounjaro 7.5mg Kwikpen is not recommended for patients under 18 years of age.
- Older adults often experience physiological changes that can affect how medications are processed. While the efficacy of this product remains consistent in the elderly, some caution is still necessary....
Dosage
Overdose
In the event of an overdose, reach out to the nearest hospital.
Missed a Dose
Administer a missed dose within 4 days; if over 4 days, skip it and continue on the regular schedule. Resume weekly dosing thereafter.
Mode of Action
How Does It Work?
- Mounjaro differs from other diabetes and weight-loss medications by targeting two hormone pathways simultaneously.
- While most treatments activate only one receptor, Mounjaro simultaneously activates both the GIP and GLP-1 receptors, providing a more comprehensive approach to blood sugar control and weight management....
- By activating the GIP Receptor pathway, Tirzepatide preserves insulin-producing pancreatic cells while acting on the brain's appetite control centres. This helps naturally reduce food cravings and portion sizes....
- Also, activating the GLP-1 receptor increases insulin sensitivity & secretion, slows gastric emptying, and reduces liver glucose production.
- This dual activation creates a synergistic therapeutic effect that exceeds the sum of individual receptor activations, improving blood sugar control and supporting weight loss.
Interactions
Interactions with other medicines
- Taking oral medications with a narrow therapeutic index, such as warfarin or digoxin, may be affected by tirzepatide, as it can alter their absorption.
- Using medications that require a rapid onset of action might be problematic since tirzepatide may delay their effects.
- Relying on oral contraceptives may be risky, as tirzepatide could reduce their effectiveness. It is advisable to consider switching to a non-oral contraceptive method or to use additional protection for four weeks after starting tirzepatide or increasing its dose....
- Having obesity or being overweight while using oral contraceptives may be concerning since tirzepatide can influence their efficacy.
- Frequently taking paracetamol might be impacted by tirzepatide, as it may delay its absorption; however, no dose adjustment is typically necessary.
Content Details
WRITTEN BY
Ravindra Ghongade
B. Pharm
REVIEWED BY
Dr. Nikita Toshi
BDS (Bachelor of Dental Surgery), WHO FIDES member
Frequently Asked Questions (FAQs)
Q: How exactly will Mounjaro 7.5mg KwikPen help me manage my type 2 diabetes and weight?
A: Mounjaro 7.5mg KwikPen, which contains the active ingredient tirzepatide, works through a dual mechanism by mimicking the actions of two natural hormones, GLP-1 and GIP. This combined effect is highly beneficial for improving blood sugar control in adults with type 2 diabetes. It helps stimulate the release of insulin, limits the sugar produced by the liver, and delays gastric emptying. Additionally, this action influences the brain's appetite centers, reducing hunger and cravings. When combined with a reduced-calorie diet and increased physical activity, Mounjaro 7.5mg KwikPen effectively aids in both blood sugar regulation and weight management.
Q: I'm worried about side effects, especially nausea and diarrhea. What can I do to minimize them?
A: Common gastrointestinal side effects like nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion are often experienced with Mounjaro 7.5mg KwikPen, especially when starting treatment. Generally, these symptoms are mild and tend to decrease over time. To help alleviate nausea, try eating smaller, more frequent, and balanced meals, and avoid high-fat or heavy foods. Crucially, ensure adequate hydration, particularly if you are vomiting or experiencing diarrhea, to prevent dehydration. If any of these side effects become severe or do not improve, you should seek immediate consultation with your doctor.
Q: I use oral birth control pills. Do I need to take any special precautions while on Mounjaro 7.5mg KwikPen?
A: Yes, if you are using oral contraceptive pills, special precautions are necessary. The Mounjaro 7.5mg KwikPen can potentially slow down the rate at which your stomach empties, which may reduce how effectively your body absorbs oral medications, including birth control pills. Due to this risk of reduced effectiveness, it is strongly recommended that you use a non-oral contraceptive method or an additional barrier method (like condoms) for a period of four weeks after starting Mounjaro 7.5mg KwikPen and for four weeks following any subsequent increase in your dosage.
Q: Are there any serious health conditions that mean I absolutely cannot take Mounjaro 7.5mg KwikPen?
A: There are specific conditions where the Mounjaro 7.5mg KwikPen is strictly contraindicated. You should not use this medication if you are allergic to tirzepatide or any of its components. Furthermore, it is not advised for patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The Mounjaro 7.5mg KwikPen must also be avoided during pregnancy due to potential risks, and women planning to conceive should discontinue its use at least one month before their intended pregnancy date.
Q: What are Mounjaro’s available strengths and typical uses?
- Mounjaro is a once-weekly injection administered subcutaneously and is available in various strengths to allow for a personalised treatment plan.
- The medication typically begins with a 2.5 mg dose, which is used to initiate therapy and help the body adjust. After this initial phase, most patients move to the 5 mg dose, which is commonly prescribed as a regular maintenance dose....
- If further blood sugar control is needed, the dose may be increased to 7.5 mg, followed by 10 mg for greater therapeutic effect.
- For patients requiring stronger results, 12.5 mg may be considered, and the maximum approved dose is 15 mg.
- The decision to adjust the dose depends on individual response, tolerability, and overall treatment goals, and should always be guided by your doctor.
Q: Should I rotate injection sites?
A: Yes, switch between your thigh, stomach, and upper arm to prevent skin irritation and ensure the medication works properly.
Q: Are there any precautions to follow while taking Mounjaro 7.5mg Kwikpen?
- Yes, some important precautions include:
- Monitor for low blood sugar if you're taking other diabetes medications.
- Stay hydrated, particularly if you experience stomach upset.
- Avoid or limit alcohol, as it can increase the risk of low blood sugar or dehydration.
- Inform your doctor if you have a history of pancreatitis, kidney disease, or severe gastrointestinal issues.
- If you're undergoing surgery, notify your doctor that you're taking Mounjaro 7.5mg Kwikpen, as it can slow stomach emptying and may need to be suspended prior to the procedure.
- For women using oral birth control, discuss alternative or additional contraception with your doctor.
References
View All
- Lilly.com | Eli Lilly and Company [Internet]. www.lilly.com. [Cited 7 August 2025]
- Mounjaro KwikPen 2.5mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) [Internet]. www.medicines.org.uk. [Cited 7 August 2025]
- MOUNJAROTM (tirzepatide) Injection, for subcutaneous use. Initial U.S. Approval: 2022 [Internet]. uspl.lilly.com. [Cited 7 august 2025]
Did you find this medicine information helpful?
Please rate your experience
Product Details
Brand
MOUNJARO
Country of Origin
Usa
Expiry Date
30/08/2027
Manufacturer Details
Other Products from this Brand
View All
- MOUNJARO KWIKPEN 2.5MG PRE FILLED PEN OF 2.4ML SOLUTION FOR INJECTION
- MOUNJARO KWIKPEN 10MG PRE FILLED PEN OF 2.4ML SOLUTION FOR INJECTION
- MOUNJARO KWIKPEN 12.5MG PRE FILLED PEN OF 2.4ML SOLUTION FOR INJECTION
- MOUNJARO KWIKPEN 15MG PRE FILLED PEN OF 2.4ML SOLUTION FOR INJECTION
- MOUNJARO KWIKPEN 5MG PRE FILLED PEN OF 2.4ML SOLUTION FOR INJECTION
- MOUNJARO 2.5MG VIAL OF 0.5ML SOLUTION FOR INJECTION
- MOUNJARO 5MG VIAL OF 0.5ML SOLUTION FOR INJECTION
Blog Articles
Chronic Condition Articles
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.
Please add item(s) to proceed
